1. Home
  2. EVF vs BMEA Comparison

EVF vs BMEA Comparison

Compare EVF & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Senior Income Trust

EVF

Eaton Vance Senior Income Trust

HOLD

Current Price

$5.27

Market Cap

95.9M

Sector

Finance

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.31

Market Cap

98.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVF
BMEA
Founded
1998
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.9M
98.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EVF
BMEA
Price
$5.27
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.71
AVG Volume (30 Days)
93.3K
1.4M
Earning Date
01-01-0001
11-04-2025
Dividend Yield
10.68%
N/A
EPS Growth
N/A
N/A
EPS
0.94
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.20
$0.87
52 Week High
$6.84
$4.23

Technical Indicators

Market Signals
Indicator
EVF
BMEA
Relative Strength Index (RSI) 43.13 52.68
Support Level $5.28 $1.03
Resistance Level $5.32 $1.32
Average True Range (ATR) 0.04 0.10
MACD -0.01 -0.01
Stochastic Oscillator 21.50 61.19

Price Performance

Historical Comparison
EVF
BMEA

About EVF Eaton Vance Senior Income Trust

Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: